Glycine Injection Solution

Glycine Injection Solution

Available presentation(s): 10 mL. Verify the exact concentration and total active quantity on the prescription and dispensing label.

Introduction: Glycine is a non-essential amino acid and inhibitory neurotransmitter. Parenteral glycine as a stand-alone compounded wellness injection has no established standard indication or regimen.

Dosage: No validated standard dose is available for the 50 mg/mL compounded injection. Prescriptions must state exact dose, route, dilution/rate if infused, treatment goal and monitoring. Consider total amino-acid and fluid exposure.

Mechanisms of Action: Serves as a substrate for protein, glutathione, creatine, haem and purine synthesis and activates inhibitory glycine receptors in the central nervous system.

Contraindications & Precautions: Use caution in significant renal or hepatic impairment and in disorders affecting amino-acid metabolism. Evaluate osmolarity and compatibility. Neurologic or electrolyte effects are possible with excessive exposure.

Interactions: Clinically relevant interactions are not well characterised. Additive CNS effects are theoretically possible; avoid unvalidated admixtures.

Adverse Reactions / Side Effects: Nausea, flushing, headache, sedation, local irritation and metabolic/electrolyte disturbances are possible; safety data for compounded injection are sparse.

Pregnancy & Breastfeeding: No adequate data support non-essential injectable use during pregnancy or breastfeeding.

Storage: Store under the conditions stated on the Optimus dispensing label and product-specific worksheet. Protect from light where labelled. Do not freeze unless explicitly validated. Maintain cold chain if the label requires refrigeration. Do not use after the assigned beyond-use date or if there is visible particulate matter, precipitation, colour change, loss of container integrity or evidence of improper storage. Once entered, follow the validated in-use time; do not assume a compounded vial is multi-dose.

References

• New Zealand Formulary (NZF), current online edition; product-specific approved data sheets where available; USP Pharmaceutical Compounding—Sterile Preparations; and Optimus Healthcare validated formulation, sterility/endotoxin controls and assigned beyond-use date.
• US FDA. Compounding and the FDA: Questions and Answers. Updated 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers